Show simple item record

dc.contributor.authorScarsi, Kimberly K.
dc.contributor.authorDarin, Kristin M.
dc.contributor.authorNakalema, Shadia
dc.contributor.authorBack, David J.
dc.contributor.authorByakika-Kibwika, Pauline
dc.contributor.authorElse, Laura J.
dc.contributor.authorPenchala, Sujan Dilly
dc.contributor.authorBuzibye, Allan
dc.contributor.authorCohn, Susan E.
dc.contributor.authorMerry, Concepta
dc.contributor.authorLamorde, Mohammed
dc.date.accessioned2022-01-13T17:35:36Z
dc.date.available2022-01-13T17:35:36Z
dc.date.issued2016
dc.identifier.citationScarsi, K. K., Darin, K. M., Nakalema, S., Back, D. J., Byakika-Kibwika, P., Else, L. J., ... & Lamorde, M. (2016). Unintended pregnancies observed with combined use of the levonorgestrel contraceptive implant and efavirenz-based antiretroviral therapy: a three-arm pharmacokinetic evaluation over 48 weeks. Clinical Infectious Diseases, 62(6), 675-682. DOI: 10.1093/cid/civ1001en_US
dc.identifier.other10.1093/cid/civ1001
dc.identifier.urihttps://nru.uncst.go.ug/xmlui/handle/123456789/1271
dc.description.abstractLevonorgestrel subdermal implants are preferred contraceptives with an expected failure rate of <1% over 5 years. We assessed the effect of efavirenz- or nevirapine-based antiretroviral therapy (ART) coadministration on levonorgestrel pharmacokinetics. Methods. This nonrandomized, parallel group, pharmacokinetic evaluation was conducted in three groups of human immunodeficiency virus–infected Ugandan women: ART-naive (n = 17), efavirenz-based ART (n = 20), and nevirapine-based ART (n = 20). Levonorgestrel implants were inserted at baseline in all women. Blood was collected at 1, 4, 12, 24, 36, and 48 weeks. The primary endpoint was week 24 levonorgestrel concentrations, compared between the ART-naive group and each ART group by geometric mean ratio (GMR) with 90% confidence interval (CI). Secondary endpoints included week 48 levonorgestrel concentrations and unintended pregnancies.en_US
dc.language.isoenen_US
dc.publisherClinical Infectious Diseasesen_US
dc.subjectContraceptive implanten_US
dc.subjectLevonorgestrelen_US
dc.subjectEfavirenzen_US
dc.subjectNevirapineen_US
dc.subjectUnintended pregnancyen_US
dc.titleUnintended Pregnancies Observed With Combined Use of the Levonorgestrel Contraceptive Implant and Efavirenz-based Antiretroviral Therapy: A Three-Arm Pharmacokinetic Evaluation Over 48 Weeksen_US
dc.typeArticleen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record